# Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

> **NCT06550921** · NA · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Oligometastasis
- Ablation
- Anti-PD1 Antibody
- Lenvatinib

## Interventions

- **PROCEDURE:** ablation of oligometastasis

## Key facts

- **NCT ID:** NCT06550921
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06550921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06550921, "Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06550921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*